VZV: Persistence in the population: Transmission and epidemiology

Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis

Volumn , Issue , 2007, Pages 713-734

  Seward, Jane ^a   Jumaan, Aisha ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42549161938     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545313.041     Document Type: Chapter

References (135)

1. Arvin, A. M. (1996). Varicella-zoster virus: Overview and clinical manifestations. Semin. Dermatol., 15(2 Suppl. 1), 4-7. Review.
2. Arvin, A. M., Koropchak, C. M., and Wittek, A. E., (1983). Immuno-logical evidence of re-infection with varicella zoster virus. J. Infect. Dis., 148, 200-205.
3. Asano, Y., Nakayama, H., Yazaki, T. et al. (1977). Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics, 59, 3-7.
4. Barzaga, N. G., Roxas, J. R., and Florese, R. H. (1994). Varicella zoster virus prevalence in metro Manila, Philippines. J. Am. Med. Assoc. (SE Asia), 274, S633-S635.
5. Battcock, T. M., Finn, R., Barnes, R. M. et al. (1990). Observations on herpeszoster: 1. Residualscarringandpost-herpeticneuralgia; 2. Handedness and the risk of infection. Br. J. Clin. Pract., 44(12), 596-598.
6. Boelle, P. Y. and Hanslik, T. (2002). Varicella in non-immune persons: Incidence, hospitalization and mortality rates. Epi-demiol. Infect., 129, 599-606.
7. Bowsher, D.(1999). The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia: A retrospective survey in an elderly population. Eur. J. Pain, 3, 335-342.
8. Bramley, J. C. and Jones, I. G. (2000). Epidemiology of chickenpox in Scotland: 1981 to 1998. Commun. Dis. Public Health, 3, 82-87.
9. Brisson, M. and Edmunds, J. W. (2003). Epidemiology of Varicella-Zoster Virus in England and Wales. J. Med. Virol., 70(Suppl 1), S9-S14.
10. Brisson, M., Edmunds, W. J., Law, B. et al. (2001). Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol. Infect. 127(2), 305-314.
11. Brisson, M., Gay, N. J., Edmunds, W. J. et al. (2002). Exposure to varicella boosts immunity to herpes-zoster: Implications for mass vaccination against chickenpox. Vaccine, 20(19-20), 2500-2507.
12. Buchbinder, S. P., Katz, M. H., Hessol, N. A. et al. (1992). Herpes zoster and human immunodeciency virus infection. J. Infect. Dis., 166(5), 1153-1156.
13. Centers for Disease Control and Prevention. (2003). Decline in annual incidence of varicella-selected states, 1990-2001. Morb. Mortal. Wkly Rep., 52(37), 884-885.
14. Chant, K. G., Sullivan, E. A., Burgess, M. A. et al. (1998). Varicella-zoster virus infection in Australia. Aust. N Z J. Public Health, 22, 413-418.
15. Chidiac, C., Bruxelle, J., Daures, J. P. et al. (2001). Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin. Infect. Dis, 33, 62-69.
16. Choo, P. W., Donahue, J. G., Manson, J. E., and Platt, R. (1995). The epidemiology of varicella and its complications. J. Infect. Dis., 172, 706-712.
17. Choo, P. W., Galil, K., Donahue J. G. et al. (1997). Risk factors for postherpetic neuralgia. Arch. Intern. Med., 157(11), 1217-1224.
18. Coplan, P., Black, S., Rojas, C. et al. (2001). Incidence and hospi-talization rates of varicella and herpes zoster before varicella vaccine introduction: A baseline assessment of the shiftingepi-demiology of varicella disease. Pediatr. Infect. Dis., 20(7), 641-645.
19. Davis, M. M., Patel, M. S., Chen, B. S. et al. (2004). Decline in varicella-related hospitalization and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics, 114(3), 786-792.
20. Decroix, J., Partsch, H., Gonzalez, R. et al. (2000). Factors inu-encing pain outcome in herpes zoster: An observational study with valaciclovir. Valaciclovir International Zoster Assess-ment Group (VIZA). J. Eur. Acad. Dermatol. Venereol., 14(1), 23-33.
21. Degeun, S., Chau, N. P., and Flahault, A. (1998). Epidemiology of chickenpox in France (1991-1995). J. Epidemiol. Commun. Health, 52, 46S-98S.
22. Di Luzio Paparatti, U., Arpinelli, F., and Visona, G. (1999). Herpes zoster and its complications in Italy: An observational survey. J. Infect., 38(2), 116-120.
23. Donahue, J. G., Choo, P. W., and Manson, J. E. (1995). The incidence of herpes zoster. Arch. Intern. Med., 155, 1605-1609.
24. Dworkin, R. H., Nagasako, E. M., Johnson, R. W., and Grifn, D. R. (2001). Acute pain in herpes zoster: The famciclovir database project. Pain, 94(1), 113-119.
25. Dworkin, M. S., Jennings, C. E., Roth-Thomas, J. et al. (2002). An Outbreak of Varicella among children attending preschool and elementary school in Illinois. Clin. Infect. Dis., 35(1), 102-104. Epub 2002 Jun 05.
26. Edmunds, W. J., Brisson, M., and Rose, J. D. (2001). The epidemiol-ogy of herpes zoster and potential cost-effectiveness of vacci-nation in England and Wales. Vaccine, 19(23-24), 3076-3090.
27. Enders, G. and Miller, E. (2000). Varciella and herpes zoster in preg-nancy and the newborn. In Arvin, A. and Gershon, A, eds. Varicella-Zoster Virus, pp. 317-347. Cambridge: Cambridge University Press.
28. Enders, G., Miller, E., Cradock-Watson, J. et al. (1994). Conse-quences of varicella and herpes zoster in pregnancy: Prospec-tive study of 1739 cases. Lancet, 343(8912), 1548-1551.
29. Fairley, C. K. and Miller, E. (1996). Varicella-zoster virus epidemi-ology-a changing scene J. Infect. Dis., 174(suppl 3), S314-S319.
30. Fales, W. T. (1928). The age distribution of whooping cough, measles, chickenpox, scarlet fever and diphtheria in various areas in the United States. Am. J. Hyg., 8, 759-799.
31. Feld, R., Evans, W. K., and DeBoer, G. (1980). Herpes zoster in patients with small-cell carcinoma of the lung receiving com-bined modality treatment. Ann. Intern. Med., 93(2), 282-283.
32. Fornaro, P., Gandini, F., Marin, M. et al. (1999). Epidemiology and cost analysis of varicella in Italy: Results of a sentinel study in the pediatric practice. Pediatr. Infect. Dis. J., 18, 414-419.
33. Gabutti, G., Penna, C., Rossi, M. et al. (2001). The seroepidemiology of varicella in Italy. Epidemiol. Infect., 126, 433-440.
34. Galil, K., Choo, P. W., Donahue, J. G., and Platt, R. (1997). The seque-lae of herpes zoster. Arch. Intern. Med., 157(11), 1209-1213.
35. Galil, G., Brown, C., Lin, F., and Seward, J. (2002a). Hospitalizations for varicellain the United States, 1988-1999. Pediatr. Infect. Dis. J., 21, 931-934.
36. Galil, K., Lee, B., Strine, T. et al. (2002b). Outbreak of varicella at a day-care center despite vaccination. N. Engl. J. Med., 347(24), 1909-1915.
37. Galil, K., Pletcher, M. J., Wallace, B.J. et al. (2002c). Tracking varicella deaths: Accuracy and completeness of death certicates and hospital discharge records, New York State, 1989-1995. Am. J. Public Health, 92, 1248-1250.
38. Garnett, G. P. and Ferguson, N. M. (1996). Predicting the Effect of Varicella Vaccine on Subsequent Cases of Zoster and Varicella. Rev. Med. Virol., 6(3), 151-161.
39. Garnett, G. P. and Grenfell, B. T. (1992). The epidemiology of varicella-zoster virus infections: The inuence of varicella on the prevalence of herpes zoster. Epidemiol. Infect., 108(3), 513-528.
40. Garnett, G. P., Cox, M. J., Bundy, D. A. P. et al. (1993). The age of infection with varicella-zoster virus in St, Lucia, West Indies. Epidemiol. Infect., 110, 361-372.
41. Gershon, A. A., LaRussa, P., Steinberg, S. et al. (1996). The protective effect of immunologic boosting against zoster: An analysis in leukemic children who were vaccinated against chickenpox. J. Infect. Dis., 173(2), 450-453.
42. Gershon, A., Takahashi, M., and Seward, J. (2004). Varicella vaccine. In Vaccines, 4th edn, pp. 783-823, New York.
43. W. B. Saunders. Ghebrekidan, H. Ruden, U., Cox, S. et al. (1999). Prevalence of her-pes simplex virustypes 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea. J. Clin. Virol., 12, 53-64.
44. Gilden, D. H. (2005). Varicella-zoster virus vaccine-grown-upsneed it too. N. Engl. J. Med., 352(22), 2344-2345.
45. Glynn, C., Crockford, G., Gavaghan, D. et al. (1990). Epidemiology of shingles. J. Roy. Soc. Med., 83(10), 617-619.
46. Goh, C. L. and Khoo, L. (1997). A retrospective study of the clin-ical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int. J. Dermatol., 36(9), 667-672.
47. Guess, H. A., Broughton, D. D., Melton, L. J., III, and Kurland, L. T. (1985). Epidemiology of herpes zoster in children and adolescents: A population-based study. Pediatrics, 76, 512-517.
48. Guess, H. A., Broughton, D. D., Melton, L. J. III. et al. (1986). Population-based studies of varicella complications. Pedi-atrics, 78, S723-S727.
49. Guinee, V. F., Guido, J. J., Pfalzgraf, K. A. et al. (1985). The incidence of herpes zoster in patients with Hodgkin's disease. An analysis of prognostic factors. Cancer, 56(3), 642-648.
50. Haanpaa, M., Laippala, P., and Nurmikko, T. (2000). Allodynia and pinprick hypesthesia in acute herpes zoster, and the devel-opment of postherpetic neuralgia. J. Pain Symptom Manage., 20(1), 50-58.
51. Hardy, I., Gershon, A. A., Steinberg, S. P., and LaRussa P. (1991). The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N. Engl. J. Med., 325(22), 1545-1550.
52. Helgason, S., Petursson, G., Gudmundsson, S., and Sigurdsson, J. A. (2000). Prevalence of postherpetic neuralgia after a rst episode of herpes zoster: Prospective study with long term fol-low up. Br. Med. J., 321, 794-796.
53. Hope-Simpson, R. E. (1952). Infectiousness of communicable dis-eases in the household (measles, chickenpox and mumps). Lancet, ii, 549-554.
54. Hope-Simpson, R. E. (1965). The nature of herpes zoster: A long-term study and a new hypothesis. Proc. Roy. Soc. Med., 58, 2-20.
55. Hurwitz, E. S., Gunn, W. J., Pinsky, P. F. et al. (1991). Risk of respira-tory illness associated with day-care attendance:a nationwide study. Pediatrics, 87, 62-69.
56. Izurieta, H. S., Strebel, P. M., and Blake, P. A. (1997). Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. J. Am. Med. Assoc., 278, 1495-1499.
57. Jeena, P. M., Wesley, A. G., and Coovadia, H. M. (1998). Infectious diseases at the paediatric isolation units of Clairwood and King Edward VII hospitals, Durben. Trends in admission and mor-tality rates (1985-1996) and the early impact of HIV (1994-1996). S. Afr. Med. J., 88(7), 867-872.
58. Jerant, A. F., DeGaetano, J. S., Epperly, T. D. et al. (1998). Varicella susceptibility and vaccination strategies in young adults. J. Am. Board Fam. Pract., 11, 296-306.
59. Jezek, Z., Basu, R. N., and Arya, Z. S. (1978a). Investigation of small-pox suspected cases in the nal stage of Indian smallpox erad-ication programme. Ind. J. Public Health, 22(1), 107-112.
60. Jezek, Z., Basu, R. N., Arya, Z. S. etal.(1978b). Feverwith rash surveil-lance in India. Ind. J. Public Health, 22(1), 120-126.
61. Johnson, R. W. Consequences and management of pain in herpes zoster. (2002). J. Infect. Dis., 15, 186(Suppl 1), S83-90. Review.
62. Jumaan, A. O., Yu, O., Jackson, L. A., Bohlke, K., Galil, K., and Seward, J. F. (2005). Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J. Infect. Dis., 191(12), 2002-2007.
63. Kanra, G., Tezcan, S., Badur, S. and the Turkish National Study Team. (2002). Varicella seroprevalence in a random sample of the Turkish population. Vaccine, 20(9-10), 1425-1428.
64. Kilgore, P. E, Kruszon-Moran, D., Seward, J. F. et al. (2003). Vari-cella in Americans from NHANES III: Implications for con-trol through routine immunization. J. Med. Virol., 70(Suppl 1), S111-S118.
65. Kurokawa, I., Kumano, K., Murakawa, K. et al. (2002). Clinical corre-lates of prolonged pain in Japanese patients with acute herpes zoster. J. Int. Med. Res., 30(1), 56-65.
66. Laforet, E. G. and Lynch, C. L. (1947). Multiple congenital defects following maternal varicella. N. Engl. J. Med., 236(15), 534-537.
67. Lee, B. W. (1998). Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop. Med. Int. Health, 3(11), 886-890. Review.
68. Levin, M. J. (2001). Use of varicella vaccines to preventherpes zoster in older individuals. Arch. Virol. Suppl, 17, 151-160. Review.
69. Levin, M. J., Barber, D., Goldblatt, E. et al. (1998). Use of a live atten-uated varicella vaccine to boost varicella-specic immune responses in seropositive people 55 years of age and older: Duration of booster effect. J. Infect. Dis., 178(Suppl 1), S109-S112.
70. Levin, M. J., Smith, J. G., Kaufhold, R. M. et al.(2003). Decline in varicella-zoster virus (VZV)-specic cell-mediated immunity with increasing age and boosting with a high-hose VZV vac-cine. J. Infect. Dis., 188(9), 1336-1344.
71. Lin, F. and Hadler, J. L. (2000). Epidemiology of primary varicella and herpes zoster hospitalizations: The pre-varicella vaccine era. J. Infect. Dis., 181(6), 1897-1905.
72. Locksley, R. M., Flournoy, N., Sullivan, K. M. et al. (1985). Infec-tion with varicella-zoster virus after marrow transplantation. J. Infect. Dis., 152(6), 1172-1181.
73. Lojeski, E. and Stevens, R. A. (2000). Postherpetic neuralgia in the cancer patient. Curr. Rev. Pain, 4(3), 219-226.
74. Lolekha, S., Tanthiphabha, W., Sornchai, P. et al. (2001). Effect of cli-matic factors and population density on varicella zoster virus epidemiology within a tropical country. Am. J. Trop. Med. Hyg., 64, 131-136.
75. MacIntyre, C. R., Chu, C. P., and Burgess, M. A. (2003). Use of hos-pitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol. Infect., 131(1), 675-682.
76. Mandal, B. K., Mukherjee, P. P., Murphy, C. et al. (1998). Adult sus-ceptibility to varicella in the tropics is a rural phenomenon due to lack of previous exposure. J. Infect. Dis., 178(Suppl.), S52-S54.
77. McGregor, R. M. (1957). Herpes zoster, chicken pox and cancer in general practice. Br. Med. J., 1, 84-87.
78. McNulty, A., Li, Y., Radtke, U. et al. (1997). Herpes zoster and the stage and prognosis of HIV-1 infection. Genitourin. Med., 73(6), 467-470.
79. Meyer, A., Seward, J. F., Jumaan, A. O., and Wharton, M. (2000). Vari-cella mortality: Trends before vaccine licensure in the United States, 1970-94. J. Infect. Dis., 182, 383-390.
80. Miller, A. E. (1980). Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology, 30(6), 582-587.
81. Morgan, D., Mahe, C., Malamba, S. et al. (2001). Herpes zoster and HIV-1 infection in a rural Ugandan cohort. AIDS, 15(2), 223-229.
82. Nader, S., Bergen, R., Sharp, M., and Arvin, A. M. (1995). Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J. Infect. Dis., 171(1), 13-17.
83. Nagasako, E. M., Johnson, R. W., Grifn, D. R. et al. (2002). Rash severity in herpes zoster: Correlates and relationship to pos-therpetic neuralgia. J. Am. Acad. Dermatol., 46(6), 834-839.
84. Nguyen, H., Jumaan, A. O., and Seward, J. F. (2005). Decline in mor-tality due to varicella after implementation of varicella vacci-nation in the United States. N. Engl. J. Med., 352, 450-458.
85. Oh, H. M., Ho, A. Y., Chew, S. K. et al. (1997). Clinical presentation of herpes zosterina Singapore hospital. Singapore Med. J., 38(11), 471-474.
86. Ooi, P. L., Goh, K. T., Doraisingham, S., and Ling, A. E. (1992). Preva-lence of varicella-zoster virus infection in Singapore. Southeast Asian J. Trop. Med. Public Health, 23, 22-25.
87. Opstelten, W., Mauritz, J. W., de Wit, N. J. et al. (2002). Herpes zoster and postherpetic neuralgia: Incidence and risk indica-tors using a general practice research database. Fam. Pract., 19(5), 471-475.
88. Oxman, M. N. (1995). Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology, 45(Suppl. 8), S41-S46.
89. Oxman, M. N., Levin, M. J., Johnson, G. R. et al. (2005). A vaccine to prevent herpes zoster and postherpetic neuragia in order adults. N. Engl. J. Med., 352(22), 2271-2284.
90. Palmer, S. R., Caul, E. O., Donald, D. E., Kwantes, W., and Tillett, H. (1985). An outbreak of shingles Lancet, 2(8464), 1108-1111.
91. Petursson, G., Helgason, S., Gudmundsson, S. et al. (1998). Her-pes zoster in children and adolescents. Pediatr. Infect. Dis. J., 17(10), 905-908.
92. Ragozzino, M. W., Melton, L. J. 3rd, Kurland, L. T. et al. (1982). Population-based study of herpes zoster and its sequelae. Medicine (Baltimore), 61(5), 310-316.
93. Ratner, A. J.(2002). Varicella-related hospitalizations in the vaccine era. Pediatr. Infect. Dis. J., 21, 927-930.
94. Rawson, H., Crampin, A., and Noah, N. (2001). Deaths from chick-enpox in England and Wales 1995-97: Analysis of routine mor-tality date. Br. Med. J., 323, 1091-1093.
95. Reigle, L. and Cooperstock, M. (1985). Contagiousness of zoster in a day care setting. Pediatr. Infect. Dis., 4(4), 413.
96. Reis, A. D., Pannuti, C. S., and de Souza, V. A. (2003). Prevalence of varicella-zoster virus antibodies in young adults from different Brazilian climatic regions. Rev. Soc. Bras. Med. Trop., 36(3), 317-320. Epub 2003 Jul 31.
97. Ross, A. H. (1962). Modication of chickenpox in family contacts by administration of gamma globulin. N. Engl. J. Med., 267, 369-376.
98. Ross, A. M. and Fleming, D. M. (2000). Chickenpox increasingly affects preschool children. Commun. Dis. Public Health, 3, 213-215.
99. Rusthoven, J. J. (1994). The risk of varicella-zoster infections in dif-ferent patient populations:a critical. Transfus. Med. Rev., 8(2), 96-116.
100. Rusthoven, J. J., Ahlgren, P., Elhakim, T. et al. (1988). Risk factors for varicella zoster disseminated infection among adult cancer patients with localized zoster. Cancer, 62(8), 1641-1646.
101. Rusthoven, J. J., Ahlgren, P., Elhakim, T. et al. (1988). Varicella-zoster infection in adult cancer patients. A population study. Arch. Intern. Med., 148(7), 1561-1566.
102. Ryan, M. A, Smith, T. C., Honner, W. K. et al. (2003). Varicella susceptibility and vaccine use among young adults enlisting in the United States Navy. J. Med. Virol., 70(Suppl 1), S15-S19.
103. Schimpff, S., Serpick, A., Stoler. B. et al. (1972). Varicella-Zoster infection in patients with cancer. Ann. Intern. Med., 76(2), 241-254.
104. Schmader, K. (2000). Epidemiology of herpes zoster. In Arvin, A. and Gershon, A., eds. Varicella-Zoster Virus, pp. 220-245, Cambridge: Cambridge University Press.
105. Schmader, K. (2001). Herpes zoster in older adults. Clin. Infect. Dis., 32(10), 1481-1486.
106. Schmader, K., Studenski, S., MacMillan, J. et al. (1990). Are stressful life events risk factors for herpes zoster J. Am. Geriatr. Soc., 38(11), 1188-1194.
107. Schmader, K., George, L. K., Burchett, B. M. et al. (1995). Racial differences in the occurrence of herpes zoster. J. Infect. Dis., 171(3), 701-704.
108. Schmader, K., George. L. K., Burchett, B. M. et al. (1998). Race and stress in the incidence of herpes zoster in older adults. J. Am. Geriatr. Soc., 46(8), 973-977.
109. Schoub, B. D., Johnson. S., McAnerney, J. M. et al. (1985). Prevalence of antibodies to varicella zoster virus in healthy adults. S. Afr. Med. J., 8, 67(23), 929-931.
110. Schuchter, L. M., Wingard, J. R., Piantadosi, S. et al. (1989). Herpes zoster infection after autologous bone marrow transplanta-tion. Blood, 74(4), 1424-1427.
111. Seiler, H. E. (1949). A study of herpes zoster particularly in relation to chickenpox. J. Hyg. (Lond.), 47, 253-262.
112. Seward, J. Meyer, P., Singleton, J. et al. (1998). Varicella incidence and mortality, USA 1970-1994. Infectious Disease Society of America. 36th Annual Meeting, Denver, CO.
113. Seward, J., Galil, K., and Wharton, M. (2000). Epidemiology of vari-cella. In Arvin, A. and Gershon, A., eds. Varicella-Zoster Virus, pp. 187-205. Cambridge University Press.
114. Seward, J. F., Watson, B. M., Peterson, C. L. et al. (2002). Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. J. Am. Med. Assoc., 287, 606-611.
115. Socan, M., Kraigher, A., and Pahor, L. (2001). Epidemiology of vari-cella in Slovenia overa 20-year period (1979-1998). Epidemiol. Infect., 126, 279-283.
116. Solomon, B.A., Kaporis, A.G., Glass, A.T. et al. (1998). Lasting immu-nity to varicella in doctors study (L.I.V.I.D. study). Am. Acad. Dermatol., 38, 763-765.
117. Stankus, S. J., Dlugopolski, M., Packer, D. et al. (2000). Management of herpes zoster (shingles) and postherpetic neuralgia. Am. Fam. Physician, 61(8), 2437-2444, 2447-2448. Review.
118. Takayama, N., Yamada, H., Kaku, H. et al. (2000). Herpes zoster in immunocompetent and immunocompromised Japanese. Pediatr. Int., 42(3), 275-279.
119. Terada, K., Hirago, U., Kawano, S. et al. (1995). Incidence of herpes zoster in pediatricians and history of reexposure to varicella-zoster virus in patients with herpes zoster. Kansenshogaku Zasshi, 69(8), 908-912.
120. Thiry, N., Beutels, P., Shkedy, Z. et al. (2002). The seroepidemiol-ogy of primary varicella-zoster virus infection in Flanders (Bel-gium). Eur. J. Pediatr., 161, 588-593.
121. Thomas, S.L. and Hall, A.J. (2004). What does epidemiology tell us about risk factors for herpes zoster Lancet Infect. Dis., 4(1), 26-33. Review.
122. Thomas, S. L., Wheeler, J. G., Hall, A. J. et al. (2002). Contacts with varicella or with children and protection against herpes zoster in adults:a case-control study. Lancet, 31, 360 (9334), 678-682.
123. Tobias, M., Reid, S., Lennon, D. et al. (1998). Chickenpox immu-nization in New Zealand. NZ Med. J., 111, 274-281.
124. Tzeng, C. H., Liu, J. H., Fan, S. et al. (1995). Varicella zoster virus infection after allogeneic or autologous hemopoietic stem cell transplantation. Factors contributing to severity of herpes zoster in children. Pediatrics, 67(5), 763-771.
125. Veenstra, J., van Praag, R.M., Krol, A. et al. (1996) Complications of varicella zoster virus reactivation in HIV-infected homosexual men. AIDS, 10(4), 393-399.
126. Vynnycky, E. Gay, N. J., and Cutts, F. T. (2003). The predicted impact of private sector MMRvaccination on the burden of Congenital Rubella Syndrome. Vaccine, 21(21-22), 2708-2719.
127. Wharton, M. (1996). The epidemiology of varicella-zoster virus infections. Infect. Dis. Clin. North. Am., 10(3), 571-581.
128. Whitley, R. J., Shukla, S., Crooks, R. J. et al. (1998). The identication of risk factors associated with persistent pain following herpes zoster. J. Infect. Dis., 178(Suppl 1), S710-S715.
129. Whitley, R. J., Weiss H. L., Soong, S. J. et al. (1999). Herpes zoster: Risk categories for persistent pain. J. Infect. Dis., 179, 9-15.
130. Wilson, J. B. (1986) Thirty one years of herpes zoster ina rural prac-tice. Br. Med. J. (Clin. Res. edn), 293, 1349-1351.
131. Yawn, B. P., Yawn, R. A., and Lydick, E. (1997). Community impact of childhood varicella infections. J. Pediatr., 130, 759-765.
132. Yih, W. K., Brooks, D. R., Lett, S. M. et al. (2005). The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health, 5(1), 68.
133. Yorke, J. A. and London, W. P. (1973). Recurrent outbreaks of measles, chickenpox and mumps. II. Systematic differences in contact rates and stochastic effects. Am. J. Epidemiol., 98(6), 469-482.
134. Zak-Prelich, M., Borkowski, J. L., Alexander, F. et al. (2000). The role of solar ultraviolet irradiation in zoster. Epidemiol. Infect, 129(3), 593-597.
135. Zhou, F., Harpaz, R., Jumaan, A. O., Winston, C. A., and Shefer, A. (2005). Impact of varicella vaccination on health care utiliza-tion. J. Am. Med. Assoc., 294(7), 797-802.